FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1891489226> ?p ?o ?g. }

• W1891489226 endingPage "1201" @default.
• W1891489226 startingPage "1185" @default.
• W1891489226 abstract "Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer. Response, in the form of pathological complete response, is a validated and evaluable surrogate end point of survival after neoadjuvant therapy. Thus, pathological complete response has become a primary end point for clinical trials. However, there is a current lack of uniformity in the definition of pathological complete response. A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites involved in such trials identified marked variability in specimen handling and histologic reporting. An international working group was convened to develop practical recommendations for the pathologic assessment of residual disease in neoadjuvant clinical trials of breast cancer and information expected from pathology reports. Systematic sampling of areas identified by informed mapping of the specimen and close correlation with radiological findings is preferable to overly exhaustive sampling, and permits taking tissue samples for translational research. Controversial areas are discussed, including measurement of lesion size, reporting of lymphovascular space invasion and the presence of isolated tumor cells in lymph nodes after neoadjuvant therapy, and retesting of markers after treatment. If there has been a pathological complete response, this must be clearly stated, and the presence/absence of residual ductal carcinoma in situ must be described. When there is residual invasive carcinoma, a comment must be made as to the presence/absence of chemotherapy effect in the breast and lymph nodes. The Residual Cancer Burden is the preferred method for quantifying residual disease in neoadjuvant clinical trials in breast cancer; other methods can be included per trial protocols and regional preference. Posttreatment tumor staging using the Tumor–Node–Metastasis system should be included. These recommendations for standardized pathological evaluation and reporting of neoadjuvant breast cancer specimens should improve prognostication for individual patients and allow comparison of treatment outcomes within and across clinical trials." @default.
• W1891489226 created "2016-06-24" @default.
• W1891489226 creator A5001315712 @default.
• W1891489226 creator A5003897511 @default.
• W1891489226 creator A5006346528 @default.
• W1891489226 creator A5007286394 @default.
• W1891489226 creator A5011363732 @default.
• W1891489226 creator A5011410319 @default.
• W1891489226 creator A5033544737 @default.
• W1891489226 creator A5033698551 @default.
• W1891489226 creator A5038698814 @default.
• W1891489226 creator A5043086504 @default.
• W1891489226 creator A5051903307 @default.
• W1891489226 creator A5061340891 @default.
• W1891489226 creator A5063255504 @default.
• W1891489226 creator A5070311236 @default.
• W1891489226 creator A5071060970 @default.
• W1891489226 creator A5072789687 @default.
• W1891489226 creator A5079421768 @default.
• W1891489226 creator A5086990455 @default.
• W1891489226 creator A5088697304 @default.
• W1891489226 date "2015-09-01" @default.
• W1891489226 modified "2023-10-18" @default.
• W1891489226 title "Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group" @default.
• W1891489226 cites W12086493 @default.
• W1891489226 cites W1574811228 @default.
• W1891489226 cites W1956784352 @default.
• W1891489226 cites W1963704957 @default.
• W1891489226 cites W1976240678 @default.
• W1891489226 cites W1979253447 @default.
• W1891489226 cites W1982053079 @default.
• W1891489226 cites W1989118158 @default.
• W1891489226 cites W1991307975 @default.
• W1891489226 cites W1993702531 @default.
• W1891489226 cites W1996627793 @default.
• W1891489226 cites W1999466101 @default.
• W1891489226 cites W2001119371 @default.
• W1891489226 cites W2004024603 @default.
• W1891489226 cites W2008319031 @default.
• W1891489226 cites W2016304379 @default.
• W1891489226 cites W2017098623 @default.
• W1891489226 cites W2019173289 @default.
• W1891489226 cites W2020220254 @default.
• W1891489226 cites W2023944710 @default.
• W1891489226 cites W2026686462 @default.
• W1891489226 cites W2030002770 @default.
• W1891489226 cites W2031042189 @default.
• W1891489226 cites W2047207396 @default.
• W1891489226 cites W2049189031 @default.
• W1891489226 cites W2050594705 @default.
• W1891489226 cites W2050761481 @default.
• W1891489226 cites W2058085109 @default.
• W1891489226 cites W2058112987 @default.
• W1891489226 cites W2059994457 @default.
• W1891489226 cites W2061259042 @default.
• W1891489226 cites W2063229197 @default.
• W1891489226 cites W2074160453 @default.
• W1891489226 cites W2075894019 @default.
• W1891489226 cites W2080870561 @default.
• W1891489226 cites W2087179076 @default.
• W1891489226 cites W2096145980 @default.
• W1891489226 cites W2103218083 @default.
• W1891489226 cites W2104964892 @default.
• W1891489226 cites W2107073127 @default.
• W1891489226 cites W2111717465 @default.
• W1891489226 cites W2112358255 @default.
• W1891489226 cites W2112907781 @default.
• W1891489226 cites W2117305280 @default.
• W1891489226 cites W2118644184 @default.
• W1891489226 cites W2118881744 @default.
• W1891489226 cites W2119126673 @default.
• W1891489226 cites W2122008623 @default.
• W1891489226 cites W2125866630 @default.
• W1891489226 cites W2126540255 @default.
• W1891489226 cites W2126730454 @default.
• W1891489226 cites W2131811003 @default.
• W1891489226 cites W2134444110 @default.
• W1891489226 cites W2134915449 @default.
• W1891489226 cites W2138902655 @default.
• W1891489226 cites W2139707713 @default.
• W1891489226 cites W2140927379 @default.
• W1891489226 cites W2144535237 @default.
• W1891489226 cites W2147415463 @default.
• W1891489226 cites W2148103659 @default.
• W1891489226 cites W2148230878 @default.
• W1891489226 cites W2149579505 @default.
• W1891489226 cites W2150134401 @default.
• W1891489226 cites W2151552922 @default.
• W1891489226 cites W2163556848 @default.
• W1891489226 cites W2171655986 @default.
• W1891489226 cites W2172114428 @default.
• W1891489226 cites W2600395630 @default.
• W1891489226 cites W4248525000 @default.
• W1891489226 cites W4294413353 @default.
• W1891489226 doi "https://doi.org/10.1038/modpathol.2015.74" @default.
• W1891489226 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26205180" @default.
• W1891489226 hasPublicationYear "2015" @default.
• W1891489226 type Work @default.

• next